The use of nimodipine in the treatment of mood disorders

Bipolar Disorders

Volumn 2, Issue 3 PART 1, 2000, Pages 165-173

  Goodnick, Paul J ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Bipolar disorder; Calcium channels; Depression; Mania; Nimodipine

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CATECHOLAMINE; NIMODIPINE; SEROTONIN; SOMATOSTATIN;

ARTICLE; BIPOLAR DISORDER; DRUG EFFECT; HUMAN; METABOLISM; MOOD DISORDER; NERVE TRACT; PERIODICITY; RECURRENT DISEASE;

ACTIVITY CYCLES; BIPOLAR DISORDER; CALCIUM CHANNEL BLOCKERS; CATECHOLAMINES; HUMANS; MOOD DISORDERS; NEURAL PATHWAYS; NIMODIPINE; RECURRENCE; SEROTONIN; SOMATOSTATIN;

EID: 0034279236     PISSN: 13985647     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-5618.2000.020303.x     Document Type: Short Survey

References (63)

1. Dubovsky SL. Calcium antagonists: a new class of psychotropic drugs. Psychiatris Ann 1986; 16: 724-728.
2. Dubovsky SL, Franks RD. Intracellular calcium ions in affective disorders: a review and an hypothesis. Biol Psychiatry 1983; 18: 781-797.
3. Pollack MH, Rosenbaum JF, Hyman SE. Calcium channel blockers in psychiatry. Psychosomatics 1987; 28: 356-369.
4. Carman JS, Wyatt RJ. Calcium: bivalent cation in the bivalent psychoses. Biol Psychiatry 1979; 14: 295-336.
5. Goodwin FK, Jamison KR. Manic-Depressive Illness. New York: Oxford University Press, 1990.
6. Weston PG, Howard MQ. The determination of Na, K, Ca, and Mg in the blood and spinal fluid of patients suffering from manic-depressive insanity. Arch Neurol Psychiatry 1922; 8: 179-183.
7. Jimerson DC, Post RM, Carman JS et al. CSF calcium: clinical correlates in affective illness and schizophrenia. Biol Psychiatry 1979; 14: 37-51.
8. Dubovsky SL, Murphy DL, Christiano J. The calcium second messenger in bipolar disorders: data supporting new research directions. J Neuropsychiatry 1992; 4: 3-14.
9. Wood K. The neurochemistry of mania: the effect of lithium on catecholamines, indoleamines, and calcium mobilization. J Affect Disord 1985; 8: 215-223.
10. Gerner RH, Post RM, Spiegel AM. Effects of parathormone and lithium treatment on calcium and mood in depressed patients. Biol Psychiatry 1977; 12: 145-151.
11. Linder J, Levin K, Saaf J. Influence of lithium treatment on calcium and magnesium in plasma and erythrocytes. Lithium 1993; 4: 115-123.
12. Langley MS, Sorkin EM. Nimodipine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cerebrovascular disease. Drugs 1989; 37: 669-699.
13. Steen PA, Newberg LA, Milde JH, Michenfelder JD. Nimodipine improves cerebral blood flow and neurologic recovery after complete cerebral ischemia in the dog. J Cereb Blood Flow Metab 1983; 3: 38-43.
14. Kass IS, Cottrell JE, Chambers G. Magnesium and cobalt, not nimodipine, protect neurons against anoxic damage in the rat hippocampal slice. Anesthesiology 1988; 69: 710-715.
15. 2+ -release from rat brain microsomes. Biol Psychiatry 1996; 40: 497-502.
16. 2+ channels to homosynaptic long-term depression in the CAl region in vitro. J Neurophysiol 1997; 77: 1651-1655.
17. Medical Economics Company. Physician's Desk Reference, 53rd edn. Montvale: Medical Economics Company, 1999.
18. Reynolds JEF. Martindale: The Extra Pharmacopoeia. London: The Pharmaceutical Press, 1993.
19. Fuhr U, Maier-Bruggemann A, Blume H et al. Grapefruit juice increases oral nimodipine bioavailability. Int J Clin Pharmacol Ther 1998; 36 (3): 126-132.
20. Rubinow DR, Gold PW, Post RM, Ballenger JC, Reichlin S. Cerebrospinal fluid somatostatin in primary affective disorder. Psychopharmacol Bull 1983; 19: 422-425.
21. Pazzaglia PJ, George MS, Post RM, Rubinow DS, Davis CL. Nimodipine increases CSF somatostatin in affectively ill patients. Neuropsychopharmacology 1995; 13: 75-83.
22. 2+ and interference with distal secretory events. Metabolism 1990; 39: 101-104.
23. Katakami H, Arimura A, Frohman LA. Involvement of hypothalamic somatostatin in the suppresion of growth hormone secretion by central corticotropin-releasing factor in conscious male rats. Neuroendocrinology 1985; 41: 390-393.
24. Rothman S. Synaptic release of excitatory amino acid neurotransmitter mediates anoxic neuronal death. J Neurosci 1984; 4: 1884-1891.
25. Tartara A, Maurelli M, Savoldi F. Synchronizing, sedative, and anticonvulsive effects of centrally administered somatostatin in the conscious rabbit. Regul Pept 1984; 9: 77-86.
26. de Falco FA, Bartiromo U, Majello L, Di Geronimo G, Mundo P. Calcium antagonist nimodipine in intractable epilepsy. Epilepsia 1992; 33: 343-345.
27. De Vry J, Fritze J, Post RM. The management of coexisting depression in patients with dementia: potential of calcium channel antagonists. Clin Neuropharmacol 1997; 20 (1): 22-35.
28. Cohen C, Perrault GH, Sanger DJ. Assessment of the antidepressant-like effects of L-type voltage-dependent channel modulators. Behav Pharmacol 1997; 8: 629-638.
29. DeVry J, Jentzsch KR, Eckel G. Effects of 1-type calcium channel antagonist nimodipine in animal models of depression. Behav Pharmacol 1996; 7: 28.
30. 2+ channels. Molec Pharmacol 1997; 50: 1284-1294.
31. Viveros MP, Martin S, Ormazabal MJ, Alfaro MJ, Martin MI. Effects of nimodipine and nifedipine upon behavior and regional brain monoamines in the rat. Psychopharmacology 1996; 127: 123-132.
32. Semkina GA, Masievskii DD, Mirozian RS. Nimodipine, nifedipine, and cererbrovascular effects of serotonin. Eksp Klin Farmakol 1996; 59 (6): 13-16.
33. Jalonen TO, Margraf RR, Wielt DB, Charniga CJ, Linne M-L, Kimelberg HK. Serotonin induces inward potassium and calcium currents in rat cortical astrocytes. Brain Res 1997; 758: 69-82.
34. Gaggi R, Dall'Olio R, Santangelo M, Roncada P. Actions of nimodipine on the serotonergic systems of rat brain. Gen Pharmacol 1997; 29 (3): 415-419.
35. Bayliss DA, Li YW, Talley EM. Effects of serotonin on caudal raphe neurons: inhibition of - and P/Q-type calcium channels and the after hyperpolarization. J Neurophysiol 1997; 77 (3): 1362-1374.
36. DeVry J, Jentzsch KR. Discriminative stimulus properties of the 5-HT1a receptor agonist BAY × 3702 in the rat. Eur J Pharmacol 1998; 357: 1-8.
37. Kozlovskii VI, Prakhe IV, Kenumen OG. The influence of calcium channel blockers on effects of haloperidol and phenamine in mice and rats. Eksp Klin Farmakol 1996; 59 (3): 12-15.
38. Nakagawa T, Ukai K, Ohyama T, Gomita Y, Okamura H. Effects of dopaminergic agents on reversal of reserpine-induced impairment in conditioned avoidance responses in rats. Pharmacol Biochem Behav 1997; 58 (4): 829-836.
39. Bhugra P, Gulati OD. Interaction of calcium channel blockers with different agonists in aorta from normal and diseased rats. Indian J Physiol Pharmacol 1996; 40 (2): 109-119.
40. 2+ influx and release in porcine myometrial cells. Biol Reprod 1997; 56 (5): 1343-1350.
41. 2+ entry associated with al-adrenoceptors in rat aorta. Naunyn-Schmiedeberg's Arch Pharmacol 1997; 356: 83-89.
42. Huang C-C, Wang S-J, Gean P-W. Selective enhancement of P-type calcium currents by isoproterenol in the rat amygdala. J Neurosci 1998; 18 (6): 2276-2282.
43. 2+ channel but not Na channel activation in porcine adrenal chromaffin cells. J Pharmacol Exp Ther 1996; 277 (3): 1209-1214.
44. Sayer RJ. Group I metabotropic glutamate receptors mediate slow inhibition of calcium current in neocortical neurons. J Neurophysiol 1998; 80 (4): 1981-1988.
45. 2+ currents in pyramidal neurons of the adult rat. Exp Brain Res 1998; 119 (2): 237-244.
46. Stuiver BT, Douma BR, Bakker R, Nyakas C, Luiten PG. In vivo protection against NMDA-induced neurodegeneration by MK-801 and nimodipine. Combined therapy and temporal course of protection. Neurodegeneration 1996; 5 (2): 153-159.
47. Saunders BD, Sabbagh E, Chin WW, Kaiser UB. Differential use of signal transduction pathways in the gonadotropin-releasing hormone-mediated regulation of gonadotropin subunit gene expression. Endocrinology 1998; 139(4): 1835-1843.
48. Week J, Fallest PC, Pitt LK, Shupnik MA. Differential gonadotropin-releasing hormone stimulation of rat luteinizing hormone subunit gene transcription by calcium influx and mitogen-activated protein kinase-signaling pathways. J Neurophysiol 1998; 80 (4): 1981-1988.
49. del Pilar FM, Meizoso MJ, Lodeiro MJ, Belmonte A. Effect of desmethyl tirilazad, dizocilpine maleate, and nimodipine on brain nitric oxide synthase activity and cyclic guanosine monophosphate during cerebral ischemia in rats. Pharmacology 1998; 57 (4): 174-179.
50. Van Den Pol AN, Obrietan K, Belousov A. Glutamate hyperexcitability and seizure-like activity throughout the brain and spinal cord upon relief from chronic glutamate receptor blockade in culture. Neuroscience 1996; 74 (3): 653-674.
51. Oliver DW, Dormehl IC. Cerebral blood flow effects of sodium valproate in drug combinations in the baboon model. Arzneim-Forch Drug Res 1998; 48 (II): 1058-1063.
52. Gasior H, Kaminski R, Brudniak T, Kleinrok Z, Czuczwar SJ. Influence of nicardipine, nimodipine, and flunarizine on the anticonvulsant efficacy of antiepileptics against pentylenetetrazaol in mice. J Neural Trans 1996; 103: 819-831.
53. Brunet G, Cerlich B, Robert S, Dumas S, Souetre E, Darcourt G. Open trial of a calcium antagonist nimodipine, in acute mania. Clin Neuropharmacol 1990; 13: 224-228.
54. Grunze H, Walden J, Wolf R, Berger M. Combined treatment with lithium and nimodipine in a bipolar I manic syndrome. Prog Neuro-Psychopharmacol Biol Psychiatry 1996; 20: 419-426.
55. Montenegro R, Cornide E, Castro NM. Nimodipine in the treatment of involutional depressive syndrome. Proc First Int Nimotop Symp 1985; X: 345-358.
56. Walden J, Fritze J, Van Calker D, Berger M, Grunze H. A calcium antagonist for the treatment of depressive episodes: single case reports. J Psychiatry Res 1995; 29: 71-76.
57. Hesslinger B, Riedel H, Hellwig B, Walden J, Berger M. Phase prevention in bipolar affective disorder with nimodipine. A case report [in German]. Nervenarzt 1996; 67: 394-396.
58. Manna V. Bipolar affective disorders and role of intraneuronal calcium. Therapeutic effects of the treatment with lithium salts and/or calcium antagonist in patients with rapid polar inversion [in Italian]. Minerva Med 1991; 82 (11): 757-763.
59. Pazzaglia PJ, Post RM, Ketter TA, George MS, Marangell LB. Preliminary controlled trial of nimodipine in ultrarapid-cycling affective dysregulation. Psychiatry Res 1993; 49: 257-272.
60. McDermut W, Pazzaglia P, Huggins T et al. Use of single case analyses in off-on-off-on trials in affective illness: a demonstration of the efficacy of nimodipine. Depression 1994/1995; 2: 259-271.
61. Goodnick PJ. Nimodipine treatment of rapid-cycling bipolar disorder. J Clin Psychiatry 1995; 56: 330.
62. Pazzaglia PJ, Post RM, Ketter TA et al. Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness. J Clin Psychopharmacol 1998; 18: 404-413.
63. Dunner DL, Patrick V, Fieve RR. Rapid cycling manic depressive patients. Compr Psychiatry 1977; 18 (6): 561-566.